Yelena Y. Janjigian, MD

Yelena Y. Janjigian, MD, is chief of the Gastrointestinal Oncology Service at Memorial Sloan Kettering Cancer Center.

Articles

Dr Janjigian on 5-Year Data With Nivolumab Plus Chemotherapy in Gastric/GEJ/Esophageal Cancer

February 24th 2025

Yelena Y. Janjigian, MD, discusses 5-year follow-up findings for nivolumab plus chemotherapy vs chemotherapy alone in gastric/GEJ adenocarcinoma.

Dr Janjigian on the FDA Approval of Zolbetuximab for CLDN18.2+ Gastric/GEJ Adenocarcinoma

November 22nd 2024

Yelena Y. Janjigian, MD, discusses the significance of the FDA approval of zolbetuximab plus chemotherapy for HER2–, CLDN18.2+ gastric/GEJ adenocarcinoma.

Dr Janjigian on Final OS Results With Pembrolizumab Plus Trastuzumab and Chemo in HER2+ Gastric/GEJ Cancer

October 7th 2024

Yelena Y. Janjigian, MD, discusses final overall survival data from the phase 3 KEYNOTE-811 trial in HER2-positive metastatic gastric or GEJ adenocarcinoma.

Nivolumab Plus Chemotherapy vs Chemotherapy as First-Line Treatment for Advanced Gastric Cancer/Gastroesophageal Junction Cancer/Esophageal Adenocarcinoma: 4-Year Follow-Up of the CheckMate 649 Study

January 30th 2024

Yelena Y. Janjigian, MD, presents 4-year follow-up data from the CheckMate 649 study investigating frontline nivolumab plus chemotherapy in patients with advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma.

Dr Janjigian on Pembrolizumab/Trastuzumab/Chemotherapy in HER2+ Gastric Cancer

October 28th 2023

Yelena Y. Janjigian, MD, discusses results from the primary progression-free survival and interim overall survival analyses of the phase 3 KEYNOTE-811 trial in patients with HER2-positive metastatic gastric or gastroesophageal junction adenocarcinoma, and contextualizes these findings with previously reported data from this trial.

Breaking Ground in Breast, Lung, Gynecologic, and Gastrointestinal Cancers From ESMO 2023: Drs Tarantino, Sands, Vergote, and Janjigian

October 24th 2023

OncLive® will be LIVE with OncLive® News Network: On Location at the 2023 ESMO Congress. Each day, we will broadcast a series of interviews with top thought leaders, to learn their thoughts and reactions to data presented across oncology during the conference.

Nivolumab plus chemotherapy vs chemotherapy as first-line treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma: 3-year follow-up from CheckMate 649

February 10th 2023

Yelena Y. Janjigian, MD, reviews the 3-year follow-up data from the CheckMate 649 trial investigating nivolumab plus chemotherapy as a first-line treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma.

Gathering Insights in Gynecologic, Lung, and GI Cancers From ESMO 2022: Drs Matulonis, Peters, and Janjigian

September 11th 2022

OncLive® will be LIVE with OncLive® News Network: On Location at the 2022 ESMO Congress. Each day, we will broadcast a series of interviews with top thought leaders, to learn their thoughts and reactions to data presented across oncology during the conference.

Dr. Janjigian on the FDA Approval of Nivolumab Plus Chemotherapy in Frontline Gastric Cancer

May 11th 2021

Yelena Y. Janjigian, MD, discusses the FDA approval of nivolumab plus chemotherapy in frontline gastric cancer.

Dr. Janjigian on the Importance of Routine HER2 Testing in Gastric/GEJ Cancer

January 13th 2021

Yelena Y. Janjigian, MD, discusses the importance of routine HER2 testing in gastric/gastroesophageal cancer.

Dr. Janjigian on the Expanding Treatment Armamentarium in HER2+ Gastric Cancer

January 7th 2021

Yelena Y. Janjigian, MD, discusses the expanding treatment armamentarium in HER2-positive gastric cancer.

Dr. Janjigian on the Emergence of New Treatment Options in Esophageal and Gastric Cancer

December 11th 2020

Yelena Y. Janjigian, MD, discusses the emergence of new treatment options in esophageal and gastric cancer.

Dr. Janjigian on the Importance of First-Line Therapy Selection in Gastric Cancer

November 24th 2020

Yelena Y. Janjigian, MD, discusses the importance of selecting an optimal first-line therapy in gastric cancer.

Dr. Janjigian on the Importance of Biomarker Testing in GI Cancers

November 19th 2020

Yelena Y. Janjigian, MD, a medical oncologist at Memorial Sloan Kettering Cancer Center, discusses the importance of biomarker testing in gastrointestinal cancers.

Dr. Janjigian on Updated Results from the DESTINY-Gastric01 Trial in HER2+ Gastric Cancer

June 25th 2020

Yelena Y. Janjigian, MD, discusses updated results from the phase 2 DESTINY-Gastric01 trial in previously treated patients with HER2-positive gastric cancer.

Dr. Janjigian on Pembrolizumab Triplet in HER2+ Esophagogastric Cancer

June 17th 2020

Yelena Y. Janjigian, MD, discusses the rationale behind the plasma and tumor-based biomarker analysis of pembrolizumab in combination with trastuzumab and chemotherapy in HER2-positive metastatic esophagogastric cancer.

Dr. Janjigian on Extensive Intraoperative Peritoneal Lavage in Gastric Cancer

April 21st 2020

Yelena Y. Janjigian, MD, discusses data examining surgery plus extensive intraoperative peritoneal lavage versus surgery alone in patients with gastric cancer.

Dr. Janjigian on the JAVELIN Gastric 100 Study With Avelumab in Gastric/GEJ Cancer

April 14th 2020

Yelena Y. Janjigian, MD, discusses results from the phase III JAVELIN Gastric 100 study evaluating avelumab in gastric or gastroesophageal cancer.

Dr. Janjigian on Data With Atezolizumab/Bevacizumab Combo in HCC

January 11th 2020

Yelena Y. Janjigian, MD, discusses the improvement in efficacy and toxicity with patients with hepatocellular carcinoma who are treated with bevacizumab and atezolizumab when compared with sorafenib.

Dr. Janjigian on Immunotherapy Combinations in Gastric Cancer

March 29th 2018

Yelena Y. Janjigian, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the addition of checkpoint inhibitors to the treatment landscape for patients with gastric and esophageal cancer, as well as potential combinations being investigated.